HIMS Hims & Hers Health, Inc.
FY2025 10-K
Hims & Hers Health, Inc. (HIMS) filed its fiscal year 2025 10-K annual report with the SEC on Feb 23, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: Consumer-first digital health platform offering telehealth consultations, personalized prescription and non-prescription products, and laboratory testing
- • New 2025 offerings: Testosterone, menopause, perimenopause support, and comprehensive laboratory testing for early health risk identification
Management Discussion & Analysis
- • Revenue $2.35B in 2025, up 59% YoY from $1.48B in 2024, driven by U.S. Revenue growth $2.21B (+53%) and Rest of World Revenue $134M (+399%)
- • Online Revenue $2.31B in 2025, up 61% YoY from $1.44B; Wholesale Revenue $36.2M down 6% YoY from $38.6M
Risk Factors
- • Cybersecurity risks reviewed quarterly by Audit Committee with escalation to CTO and executive leadership
- • Head of Information Security with 20 years experience, certified CISSP, CCSP, CRISC, CCISO, reporting to CTO
Get deeper insights on Hims & Hers Health, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.